AR030901A1 - Metodos para modular la funcion de la vejiga - Google Patents

Metodos para modular la funcion de la vejiga

Info

Publication number
AR030901A1
AR030901A1 ARP010104848A ARP010104848A AR030901A1 AR 030901 A1 AR030901 A1 AR 030901A1 AR P010104848 A ARP010104848 A AR P010104848A AR P010104848 A ARP010104848 A AR P010104848A AR 030901 A1 AR030901 A1 AR 030901A1
Authority
AR
Argentina
Prior art keywords
methods
phenyl
bladder
modulate
function
Prior art date
Application number
ARP010104848A
Other languages
English (en)
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26933980&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR030901(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of AR030901A1 publication Critical patent/AR030901A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0684—Cells of the urinary tract or kidneys
    • C12N5/0686—Kidney cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2503/00—Use of cells in diagnostics
    • C12N2503/02—Drug screening
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/341—Urinary incontinence

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Emergency Medicine (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente provee métodos y composiciones farmacéuticas para mantener el control de la vejiga, para tratar incontinencia urinaria en un mamífero utilizando agonistas de los canales de potasio KCNQ, incluyendo canales de potasio KCNQ2, KCNQ3, KCNQ4 y KCNQ5, solos o en combinacion. Los compuestos utiles en estos métodos incluyen los derivados de 1,2,4-triamino-benceno descriptos en la Patente norteamericana No. 5.384.330 (Dieter et al.,) y los compuestos 3-fenil oxindol substituidos descriptos en la Patente norteamericana No. 5.565.483 (Hewawasam et al). Entre los compuestos preferidos de esta invencion está el éster etílico de ácido N-[2-amino-4-(4-fluorbencilamino)-fenilo]carbámico, denominado también retigabina.
ARP010104848A 2000-10-17 2001-10-16 Metodos para modular la funcion de la vejiga AR030901A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24107800P 2000-10-17 2000-10-17
US28142801P 2001-04-04 2001-04-04

Publications (1)

Publication Number Publication Date
AR030901A1 true AR030901A1 (es) 2003-09-03

Family

ID=26933980

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010104848A AR030901A1 (es) 2000-10-17 2001-10-16 Metodos para modular la funcion de la vejiga

Country Status (23)

Country Link
US (3) US6348486B1 (es)
EP (2) EP1326597B1 (es)
JP (2) JP2004511516A (es)
KR (1) KR20030040540A (es)
CN (1) CN1287781C (es)
AR (1) AR030901A1 (es)
AT (1) ATE314061T1 (es)
AU (2) AU2002211758A1 (es)
BR (1) BR0114718A (es)
CA (2) CA2450467C (es)
CY (1) CY1105353T1 (es)
DE (1) DE60116352T2 (es)
DK (1) DK1326597T3 (es)
ES (1) ES2253432T3 (es)
HK (1) HK1056514A1 (es)
HU (1) HUP0303288A2 (es)
IL (1) IL155090A0 (es)
MX (1) MXPA03003339A (es)
NO (1) NO20031580L (es)
NZ (1) NZ525301A (es)
PL (1) PL360903A1 (es)
TW (1) TWI287984B (es)
WO (2) WO2002032419A2 (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6348486B1 (en) * 2000-10-17 2002-02-19 American Home Products Corporation Methods for modulating bladder function
US20020183395A1 (en) * 2001-04-04 2002-12-05 Wyeth Methods for treating hyperactive gastric motility
GB0210397D0 (en) 2002-05-07 2002-06-12 Ferring Bv Pharmaceutical formulations
JP2006513154A (ja) * 2002-10-21 2006-04-20 ラモト アット テル アヴィヴ ユニヴァーシティ リミテッド カリウムチャネルおよび／または皮質ニューロン活性モジュレーターとしての、ｎ−フェニルアントラニル酸および２−ベンズイミダゾロンの誘導体
US7632866B2 (en) * 2002-10-21 2009-12-15 Ramot At Tel Aviv University Derivatives of N-phenylanthranilic acid and 2-benzimidazolone as potassium channel and/or neuron activity modulators
MXPA05010174A (es) * 2003-04-25 2005-11-08 Lundbeck & Co As H Derivados de indol e indolina sustituidos.
US20070292528A1 (en) * 2003-05-06 2007-12-20 University Hospital Of Basel Kcnma1 as a Therapeutic Target in Cancer Treatment
US20050089559A1 (en) * 2003-10-23 2005-04-28 Istvan Szelenyi Combinations of potassium channel openers and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
US20060148782A1 (en) * 2003-11-10 2006-07-06 Lundeen James E Method and medicine for treating a mammal presenting urinary incontinence, urinary urgency, or both
EP1530967B1 (en) * 2003-11-13 2006-05-03 Ferring B.V. Blister pack and solid dosage form comprising desmopressin
EP1688141A1 (en) * 2005-01-31 2006-08-09 elbion AG The use of flupirtine for the treatment of overactive bladder and associated diseases, and for the treatment of irritable bowel syndrome
WO2007084497A1 (en) * 2006-01-19 2007-07-26 Wyeth A novel rat voltage-gated potassium channel
SE528446C2 (sv) * 2006-03-02 2006-11-14 Ferring Int Ct Sa Farmaceutisk sammansättning innefattande desmopressin, kiseldioxid och stärkelse
US7960436B2 (en) * 2006-06-05 2011-06-14 Valeant Pharmaceuticals International Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and-2,3-dihydro-1H-indenes as potassium channel modulators
US20080045534A1 (en) * 2006-08-18 2008-02-21 Valeant Pharmaceuticals North America Derivatives of 1,3-diamino benzene as potassium channel modulators
US8993593B2 (en) * 2006-08-23 2015-03-31 Valeant Pharmaceuticals International N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
CA2661462C (en) * 2006-08-23 2015-09-29 Valeant Pharmaceuticals International Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators
US8722929B2 (en) * 2006-10-10 2014-05-13 Valeant Pharmaceuticals International N-[2-amino-4-(phenylmethoxy)phenyl] amides and related compounds as potassium channel modulators
JP2010511052A (ja) * 2006-11-28 2010-04-08 バレアント ファーマシューティカルズ インターナショナル カリウムチャネル調節因子としての１，４ジアミノ二環式レチガビンアナログ
DE102007012029A1 (de) 2007-03-13 2008-09-18 Grünenthal GmbH Verfahren zur Identifizierung der agonistischen Aktivität einer Zielverbindung auf einen Kaliumkanal
US8367684B2 (en) * 2007-06-13 2013-02-05 Valeant Pharmaceuticals International Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
US8563566B2 (en) 2007-08-01 2013-10-22 Valeant Pharmaceuticals International Naphthyridine derivatives as potassium channel modulators
BRPI0814986A2 (pt) 2007-08-06 2015-02-03 Serenity Pharmaceuticals Corp Métodos e dispositivos para a distribuição de fármaco desmopresina.
US7786146B2 (en) * 2007-08-13 2010-08-31 Valeant Pharmaceuticals International Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
EP2203411B1 (en) 2007-09-20 2016-01-06 Ramot at Tel-Aviv University Ltd. N-phenyl anthranilic acid derivatives and uses thereof
US20100286045A1 (en) 2008-05-21 2010-11-11 Bjarke Mirner Klein Methods comprising desmopressin
PT2296686E (pt) * 2008-05-21 2014-05-23 Ferring Bv Desmopressina orodispersível para aumentar o período inicial de sono não perturbado por noctúria
US11963995B2 (en) 2008-05-21 2024-04-23 Ferring B.V. Methods comprising desmopressin
US20100323015A1 (en) * 2008-07-18 2010-12-23 Biljana Nadjsombati Modified release formulation and methods of use
US20100120906A1 (en) * 2008-07-18 2010-05-13 Valeant Pharmaceuticals International Modified release formulation and methods of use
US20100323016A1 (en) * 2008-07-18 2010-12-23 Biljana Nadjsombati Modified release formulation and methods of use
US20130131164A1 (en) * 2010-02-19 2013-05-23 Medichem, S.A. Stabilized phenylcarbamate derivative in solid state
WO2013165575A1 (en) * 2012-04-30 2013-11-07 Scifluor Life Sciences, Llc Fluorinated 2-amino-4-(benzylamino)phenylcarbamate derivatives
US10526280B2 (en) 2014-11-13 2020-01-07 University of Pittsburgh—of the Commonwealth System of Higher Education (2-amino-4-(arylamino)phenyl carbamates
US11358930B2 (en) 2018-04-20 2022-06-14 University of Pittsburgh—of the Commonwealth System of Higher Education Selective potassium channel agonists
EP3912625A1 (en) 2020-05-20 2021-11-24 Kaerus Bioscience Limited Novel maxi-k potassium channel openers for the treatment of fragile x associated disorders

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US37460A (en) * 1863-01-20 Improvement in meat-broilers
GB9220570D0 (en) * 1991-10-21 1992-11-11 Ici Plc Therapeutic agent
DE4200259A1 (de) 1992-01-08 1993-07-15 Asta Medica Ag Neue 1,2,4-triaminobenzol-derivate und verfahren zu deren herstellung
US5565483A (en) * 1995-06-07 1996-10-15 Bristol-Myers Squibb Company 3-substituted oxindole derivatives as potassium channel modulators
DE19539861A1 (de) 1995-10-26 1997-04-30 Asta Medica Ag Verwendung von 4-Amino-4-(4-fluorbenzylamino)-1-ethoxy-carbonylaminobenzen zur Prophylaxe und Behandlung der Folgen der akuten und chronischen zerebralen Minderdurchblutung sowie neurodegenerativer Erkrankungen
US6277978B1 (en) * 1995-12-22 2001-08-21 University Of Utah Research Foundation KVLQT1—a long QT syndrome gene
DE19701694A1 (de) 1997-01-20 1998-07-23 Asta Medica Ag Neue Modifikationen des 2-Amino-4-(4-fluorbenzylamino)-l-ethoxycarbonyl-aminobenzen sowie Verfahren zu ihrer Herstellung
EP1007638B1 (en) * 1997-08-12 2007-03-07 Bristol-Myers Squibb Company Kcnq potassium channels and methods of modulating same
CA2307316C (en) 1997-10-24 2010-12-21 University Of Utah Research Foundation Kcnq2 and kcnq3-potassium channel genes which are mutated in benign familial neonatal convulsions (bfnc) and other epilepsies
AU2532299A (en) * 1998-02-17 1999-08-30 Astrazeneca Uk Limited Potassium channel polypeptide
US6133275A (en) * 1998-05-06 2000-10-17 Abbott Laboratories 3-phenylpyrrolidine alpha-1 adrenergic compounds
US6794161B1 (en) 1999-01-26 2004-09-21 Neurosearch A/S Potassium channels and genes encoding these potassium channels
ATE342279T1 (de) 1999-01-26 2006-11-15 Neurosearch As Kaliumkanäle und für diese kaliumkanäle kodierende gene
IT1312224B1 (it) * 1999-03-23 2002-04-09 Cit Alcatel Circuito pre/post-distorcitore particolarmente per sistemi aradiofrequenza microonde.
GB9915414D0 (en) 1999-07-01 1999-09-01 Glaxo Group Ltd Medical use
US6117900A (en) 1999-09-27 2000-09-12 Asta Medica Aktiengesellschaft Use of retigabine for the treatment of neuropathic pain
US6617131B2 (en) * 2000-03-21 2003-09-09 Aventis Pharma Deutschland Gmbh Nucleic acid molecule encoding the potassium channel protein, KCNQ5
CA2404896A1 (en) * 2000-04-03 2001-10-11 Lexicon Genetics Incorporated Human ion channel protein and polynucleotides encoding the same
US6376486B1 (en) * 2000-07-06 2002-04-23 American Home Products Corporation Methods of inhibiting sphincter incontinence
US6455568B2 (en) * 2000-07-06 2002-09-24 Wyeth Combination therapy for inhibiting sphincter incontinence
WO2002015902A1 (en) * 2000-08-23 2002-02-28 Merck & Co., Inc. Method of treating or preventing urinary incontinence using prostanoid ep1 receptor antagonists
US6348486B1 (en) 2000-10-17 2002-02-19 American Home Products Corporation Methods for modulating bladder function
US6613786B2 (en) * 2001-11-02 2003-09-02 Bristol-Myers Squibb Company Thiophenyl triazol-3-one derivatives as smooth muscle relaxants
WO2004065576A2 (en) * 2003-01-15 2004-08-05 Millennium Pharmaceuticals, Inc. Methods and compositions for the treatment of urological disorder using differential expressed polypeptides
CA2531019A1 (en) * 2003-06-30 2005-01-06 Takeda Pharmaceutical Company Limited Preventive/remedy for urinary disturbance
CA2536633A1 (en) * 2003-09-10 2005-03-24 Icagen, Inc. Fused ring heterocycles as potassium channel modulators
CN101203217A (zh) * 2005-04-24 2008-06-18 惠氏公司 调节膀胱功能的方法
WO2007084497A1 (en) * 2006-01-19 2007-07-26 Wyeth A novel rat voltage-gated potassium channel

Also Published As

Publication number Publication date
CN1287781C (zh) 2006-12-06
US20060252104A1 (en) 2006-11-09
DE60116352D1 (de) 2006-02-02
EP1326597A2 (en) 2003-07-16
CA2450467A1 (en) 2002-04-25
NZ525301A (en) 2004-10-29
US7160684B2 (en) 2007-01-09
CY1105353T1 (el) 2010-03-03
CA2425742A1 (en) 2002-04-25
NO20031580D0 (no) 2003-04-08
US6348486B1 (en) 2002-02-19
CN1469739A (zh) 2004-01-21
NO20031580L (no) 2003-06-14
TWI287984B (en) 2007-10-11
HK1056514A1 (en) 2004-02-20
WO2002032960A2 (en) 2002-04-25
AU2002213308A1 (en) 2002-04-29
PL360903A1 (en) 2004-09-20
EP1328550A2 (en) 2003-07-23
JP2004529611A (ja) 2004-09-30
KR20030040540A (ko) 2003-05-22
CA2450467C (en) 2011-05-24
BR0114718A (pt) 2003-10-14
IL155090A0 (en) 2003-10-31
JP2004511516A (ja) 2004-04-15
WO2002032419A3 (en) 2002-08-15
DE60116352T2 (de) 2006-06-22
ATE314061T1 (de) 2006-01-15
HUP0303288A2 (hu) 2004-01-28
WO2002032419A2 (en) 2002-04-25
WO2002032960A3 (en) 2003-04-17
AU2002211758A1 (en) 2002-04-29
EP1326597B1 (en) 2005-12-28
US20050101004A1 (en) 2005-05-12
MXPA03003339A (es) 2003-06-19
DK1326597T3 (da) 2006-02-13
ES2253432T3 (es) 2006-06-01

Similar Documents

Publication Publication Date Title
AR030901A1 (es) Metodos para modular la funcion de la vejiga
AR033095A1 (es) Metodos para el tratamiento de motilidad gastrica hiperactiva
DK0804421T3 (da) 2-((Dihydro)pyrazolyl-3'-oxymethylen)-anilider som skadedyrsbekæmpelsesmidler og fungicider
ES2194209T3 (es) Inhibidores de metaloproteasa de tiol sulfona.
ES2193252T3 (es) Quinolonas y su uso terapeutico.
BR0209238A (pt) Compostos úteis como intermediários
DE60306547D1 (de) Substituierte 3-alkyl- und 3-arylalkyl-1h-indol-1-yl-essigsäure-derivate als plasminogen aktivator inhibitor-1 (pai-1) inhibitoren
DK1038022T3 (da) Evaluering af humane papillomavirus-tilknyttede sygdomme
ATE447970T1 (de) Mittel zur behandlung von harnwegserkrankungen, umfassend mittel zur kontrolle des lpa-rezeptors
TR199901191T2 (xx) Benzamidoaldehitlerin sistein proteaz� inhibit�r� olarak kullan�m�.
DK1475377T3 (da) Indol-derivater og deres anvendelse som inhibitorer for phosphodiesterase 4
RS53279B (en) MONODISPERSE MIXTURES OF PEGYLATED NALOXOL
WO2002049628A3 (en) Methods of treating anxiety disorders
ES2185118T3 (es) Agentes herbicidas de 3-(1,2- benc-isotiazol-e-isoxazol-5-il)-2,3-(1h,3h)-pirimidindiona o-tiona, y 3-(1,2-benzisotiazol-e isoxazol - 5-il)-4-(3h)- pirimidinona o - tiona.
DE60320784D1 (de) Stände zur modulierung des knochenwachstums
DK0489836T3 (da) Lysaktiverede acyl-enzymer
DE60101372D1 (de) Pyrimidinverbindungen und ihre verwendung als modulatoren der chemokin-rezeptor-aktivität
MXPA05006368A (es) Inhibidores aminocianopiridina de proteina cinasa-2 activada por proteina cinasa activada por mitogeno.
ID29701A (id) Piringan optik dan peranti penngerak piringan optik
DK0833626T3 (da) Mono- og disulfosubstituerede anthraquioner og deres anvendelse til behandlingen af knoglematrixforstyrrelser
PE20040566A1 (es) NUEVOS INHIBIDORES DEENZIMAS CONVERTIDORAS DE INTERLEUQUINA - 1ß
MX9303605A (es) Derivados de azabicicloheptano n-substituidas, su obtencion y uso.
ES2189072T3 (es) Nuevo benzo-cicloalquenos heterociclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
CO4761036A1 (es) Mezclas fungicidas
MX9300267A (es) 2,5-diamino-4,6-dicloropirimidina y procedimiento para su preparacion.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal